Long-term macrolide therapy for non-CF bronchiectasis Source: Annual Congress 2013 –ERS/JAMA Lunchtime session "Advances in IPF, bronchiectasis and sarcoidosis" Year: 2013
Immunoregulatory effect of a 14-membered ring macrolide antibiotic in cystic fibrosis patients Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001
Long-term macrolide therapy in chronic inflammatory airway diseases Source: Eur Respir J 2009; 33: 171-181 Year: 2009
Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011
Treatment outcome of combination antibiotic therapy including clarithromycin for Mycobacterium avium complex pulmonary disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010
Long-term efficacy and safety of tobramycin 300mg/4mL nebuliser solution in patients with cystic fibrosis and chronic Pseudomonas aeruginosa infection Source: Annual Congress 2012 - Cystic fibrosis (adults and children): new aspects of risk factors, treatments and diagnosis Year: 2012
The efficacy, safety and feasibility of inhaled amikacin for the treatment of refractory non-tuberculous mycobacterial lung diseases Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
Periodical therapy with antibiotics preserves lung function in patients with bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005
Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Resistance to antimicrobial agents in patients with non-cystic fibrosis (CF) bronchiectasis Source: Eur Respir J 2005; 26: Suppl. 49, 640s Year: 2005
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic P. aeruginosa airway colonization Source: Eur Respir J 2003; 22: Suppl. 45, 514s Year: 2003
Effectiveness of itraconazole and systemic steroids in the treatment of ABPA Source: International Congress 2018 – Role of IgE and interleukin (IL)-5 in Th2-cell signatures Year: 2018
Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis Source: Eur Respir J, 54 (1) 1801896; 10.1183/13993003.01896-2018 Year: 2019
Inhaled antibiotics in non-cystic fibrosis bronchiectasis: better than oral antibiotics? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017 Year: 2018
Macrolides, mucoactive drugs and adherence for the management of bronchiectasis Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017 Year: 2018
Efficacy and safety of various antimicrobial regimens in the treatment of acute exacerbations of chronic bronchitis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005